About: Ramipril in High Risk Patients with COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ramipril in High Risk Patients with COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Ramipril in High Risk Patients with COVID-19
Creator	López-Otero, Diego Santos, Ignacio Alberto, ; Amat-Santos, Ignacio Alberto, J Román, San Benito, Tomás Borja Ibañez, ; Carrasco-Moraleja, Manuel Catalá, Pablo Del Valle, Raquel Delgado-Arana, Raúl Enrique Gutiérrez-Ibanes, ; González-Ferreiro, Rocío Gutiérrez-Ibanes, Enrique Ibañez, Borja Jiménez-Diaz, A Jiménez-Diaz, Víctor Jose, ; Luis Nombela-Franco, ; Muñoz-García, Erika Nombela-Franco, Luis Raúl Delgado-Arana, Jose Regueiro, ; Regueiro, Ander Rocío González-Ferreiro, ; Rodríguez-Gabella, Tania Sanmartin-Pena, Carlos Santos-Martinez, Sandra Valle, Raquel Víctor, ; Xoan, ;
Source	Elsevier; Medline; PMC
abstract	Abstract Background The coronavirus disease 2019 (COVID-19) is caused by SARS-CoV2 that interfaces with the renin-angiotensin-aldosterone system (RAAS) through angiotensin-converting enzyme 2 (ACE-2). This interaction has been proposed as a potential risk factor in patients treated with RAAS-inhibitors. Objectives To analyze if RAAS-inhibitors modify the risk for COVID-19. Methods RASTAVI (NCT03201185) is an ongoing randomized clinical trial randomly allocating Ramipril or control after successful transcatheter aortic valve replacement at 14 centers is Spain. We performed a non-pre-specified interim analysis to evaluate its impact on COVID-19 risk in this vulnerable population. Results As in April 1st 2020, 102 patients (50 Ramipril and 52 controls) were included in the trial. Mean age was 82.3±6.1 years, 56.9% males. Median time of Ramipril treatment was 6 months [IQR:2.9-11.4]. Eleven patients (10.8%) have been diagnosed with COVID-19 (6 in control group and 5 receiving Ramipril, HR=1.150 [95%CI: 0.351-3.768]). The risk of COVID-19 was increased in older patients (p=0.019), those with atrial fibrillation (p=0.066), lower hematocrit (p=0.084), and more comorbidities according to Society of thoracic surgeons score (p=0.065). Admission and oxygen supply was required in 4.9% (2 patients in the Ramipril and 3 in control), and 4 of them died (two in each randomized group). A higher body mass index was the only factor increasing the mortality rate (p=0.039). Conclusions In a high risk population of old patients with cardiovascular disease, randomization to Ramipril had no impact in the incidence or severity of COVID-19. This analysis supports the maintenance of RAAS-inhibitor treatment during COVID-19 crisis.
has issue date	2020-05-26(xsd:dateTime)
bibo:doi	10.1016/j.jacc.2020.05.040
bibo:pmid	32470515
has license	els-covid
sha1sum (hex)	61b4af13832c359a89dd3f2fa734f68781c115d5
schema:url	https://doi.org/10.1016/j.jacc.2020.05.040
resource representing a document's title	Ramipril in High Risk Patients with COVID-19
has PubMed Central identifier	PMC7250557
has PubMed identifier	32470515
schema:publication	J Am Coll Cardiol
resource representing a document's body	covid:61b4af13832c359a89dd3f2fa734f68781c115d5#body_text
is schema:about of	named entity 'Patients' named entity 'Patients' named entity 'COVID-19' named entity 'risk factor' named entity 'COVID' named entity 'COVID' named entity 'RAAS' named entity 'RAAS' named entity 'SARS-CoV2' named entity 'RAAS' named entity 'enzyme' named entity 'Ramipril' named entity 'Ramipril' named entity 'COVID-19' named entity 'RAAS' named entity 'angiotensin-I' named entity 'prophylactic' named entity 'inflammatory cytokines' named entity 'COVID-19' named entity 'virus' named entity 'cell surface' named entity 'downregulate' named entity 'upregulation' named entity 'cough' named entity 'myocardial infarction' named entity 'prophylactic' named entity 'infection' named entity 'respiratory disease' named entity 'spike protein' named entity 'Ramipril' named entity 'Obesity' named entity 'fever' named entity 'viral load' named entity 'dyspnea' named entity 'TAVR' named entity 'myalgia' named entity 'angiotensin' named entity 'symptomatic treatment' named entity 'ADAM17' named entity 'oxidative stress' named entity 'IFN-γ' named entity 'diastolic' named entity 'acute respiratory distress' named entity 'symptomatic infection' named entity 'angiotensin-converting enzyme 2' named entity 'COVID-19 pandemic' named entity 'SARS-CoV2' named entity 'ACE2' named entity 'prognosis' named entity 'angiotensin II'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software